Vasileiadis G I, Sakellariou V I, Kelekis A, Galanos A, Soucacos P N, Papagelopoulos P J, Babis G C
1st Orthopaedic Department, University of Athens, ATTIKON University General Hospital, Athens, Greece.
J Musculoskelet Neuronal Interact. 2010 Jun;10(2):159-65.
We present a study comparing etidronate or indomethacin for the prevention of heterotopic ossification after total hip arthroplasty in patients with hypertrophic osteoarthritis. 52 patients were divided in two groups. Group A (26 patients) received etidronate (20 mg/kg/day for 12 weeks) and Group B (26 patients) indomethacin 75 mg/day for 2 weeks. Mean follow up was 36 months (range, 18 to 50 months). The incidence of side effects was 15.4% in group A and 30.8% in group B (p=0.324). At 6 months there was no statistically significant difference in terms of clinical (p=0.532) and radiographic evaluation between the two groups (p=0.303). However, the cost of etidronate which may be as much as six times more expensive than that of indomethacin could not justify its routine prophylactic use.
我们开展了一项研究，比较依替膦酸或吲哚美辛在肥厚性骨关节炎患者全髋关节置换术后预防异位骨化的效果。52例患者被分为两组。A组（26例患者）接受依替膦酸治疗（20毫克/千克/天，持续12周），B组（26例患者）接受吲哚美辛治疗，75毫克/天，持续2周。平均随访时间为36个月（范围为18至50个月）。A组副作用发生率为15.4%，B组为30.8%（p = 0.324）。在6个月时，两组在临床（p = 0.532）和影像学评估方面（p = 0.303）均无统计学显著差异。然而，依替膦酸的成本可能比吲哚美辛贵多达六倍，这使其常规预防性使用不合理。
